Cargando…

PD-1抑制剂Nivolumab治疗相关的皮肤毒性1例

BACKGROUND AND OBJECTIVE: Nivolumab is an checkpoint inhibitor combining with programmed death-1 (PD-1) receptor on T cells, which can block the interactions between PD-1 and programmed death ligands (PD-L), including PD-L1 and PD-L2. And then block the immunosuppression mediated by the PD-1 pathway...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500497/
https://www.ncbi.nlm.nih.gov/pubmed/31014445
http://dx.doi.org/10.3779/j.issn.1009-3419.2019.04.09